349 related articles for article (PubMed ID: 30016073)
1. Quantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumors.
Dai Q; Wilhelm S; Ding D; Syed AM; Sindhwani S; Zhang Y; Chen YY; MacMillan P; Chan WCW
ACS Nano; 2018 Aug; 12(8):8423-8435. PubMed ID: 30016073
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy.
Chu D; Zhao Q; Yu J; Zhang F; Zhang H; Wang Z
Adv Healthc Mater; 2016 May; 5(9):1088-93. PubMed ID: 26989887
[TBL] [Abstract][Full Text] [Related]
4. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
[TBL] [Abstract][Full Text] [Related]
5. Advances in the Use of Multifunctional Mesoporous Silica Nanoparticles and Related Nanomaterials as Carriers for the Cancer Treatment.
Song C; Wang X; Wang Y; Yu H; Cui Y; Ma T
Curr Drug Metab; 2018; 19(2):131-141. PubMed ID: 28758578
[TBL] [Abstract][Full Text] [Related]
6. Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells.
Yu K; Zhao J; Zhang Z; Gao Y; Zhou Y; Teng L; Li Y
Int J Pharm; 2016 Jan; 497(1-2):78-87. PubMed ID: 26617314
[TBL] [Abstract][Full Text] [Related]
7. Modulation of in vitro phagocytic uptake and immunogenicity potential of modified Herceptin
Badkas A; Frank E; Zhou Z; Jafari M; Chandra H; Sriram V; Lee JY; Yadav JS
Colloids Surf B Biointerfaces; 2018 Feb; 162():271-278. PubMed ID: 29216514
[TBL] [Abstract][Full Text] [Related]
8. Silica-encapsulated gold nanoparticle dimers for organelle-targeted cellular delivery.
Cong VT; Ly NH; Son SJ; Min J; Joo SW
Chem Commun (Camb); 2017 May; 53(36):5009-5012. PubMed ID: 28426043
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.
Wyatt EA; Davis ME
Mol Pharm; 2020 Feb; 17(2):717-721. PubMed ID: 31916770
[TBL] [Abstract][Full Text] [Related]
10. Rapid and soft formulation of folate-functionalized nanoparticles for the targeted delivery of tripentone in ovarian carcinoma.
Tomasina J; Poulain L; Abeilard E; Giffard F; Brotin E; Carduner L; Carreiras F; Gauduchon P; Rault S; Malzert-Fréon A
Int J Pharm; 2013 Dec; 458(1):197-207. PubMed ID: 24084450
[TBL] [Abstract][Full Text] [Related]
11. Activatable bispecific liposomes bearing fibroblast activation protein directed single chain fragment/Trastuzumab deliver encapsulated cargo into the nuclei of tumor cells and the tumor microenvironment simultaneously.
Tansi FL; Rüger R; Böhm C; Steiniger F; Kontermann RE; Teichgraeber UK; Fahr A; Hilger I
Acta Biomater; 2017 May; 54():281-293. PubMed ID: 28347861
[TBL] [Abstract][Full Text] [Related]
12. Programmed packaging of mesoporous silica nanocarriers for matrix metalloprotease 2-triggered tumor targeting and release.
Zou Z; He X; He D; Wang K; Qing Z; Yang X; Wen L; Xiong J; Li L; Cai L
Biomaterials; 2015 Jul; 58():35-45. PubMed ID: 25941780
[TBL] [Abstract][Full Text] [Related]
13. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
14. Single peptide ligand-functionalized uniform hollow mesoporous silica nanoparticles achieving dual-targeting drug delivery to tumor cells and angiogenic blood vessel cells.
Liu Y; Chen Q; Xu M; Guan G; Hu W; Liang Y; Zhao X; Qiao M; Chen D; Liu H
Int J Nanomedicine; 2015; 10():1855-67. PubMed ID: 25834425
[TBL] [Abstract][Full Text] [Related]
15. Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies.
Colombo M; Fiandra L; Alessio G; Mazzucchelli S; Nebuloni M; De Palma C; Kantner K; Pelaz B; Rotem R; Corsi F; Parak WJ; Prosperi D
Nat Commun; 2016 Dec; 7():13818. PubMed ID: 27991503
[TBL] [Abstract][Full Text] [Related]
16. Cancer-Cell-Specific Nuclear-Targeted Drug Delivery by Dual-Ligand-Modified Mesoporous Silica Nanoparticles.
Xiong L; Du X; Kleitz F; Qiao SZ
Small; 2015 Nov; 11(44):5919-26. PubMed ID: 26426251
[TBL] [Abstract][Full Text] [Related]
17. Tumor-mesoporous silica nanoparticle interactions following intraperitoneal delivery for targeting peritoneal metastasis.
Hargrove D; Liang B; Kashfi-Sadabad R; Joshi GN; Gonzalez-Fajardo L; Glass S; Jay M; Salner A; Lu X
J Control Release; 2020 Dec; 328():846-858. PubMed ID: 33166606
[TBL] [Abstract][Full Text] [Related]
18. Capsaicin-loaded folic acid-conjugated lipid nanoparticles for enhanced therapeutic efficacy in ovarian cancers.
Lv L; Zhuang YX; Zhang HW; Tian NN; Dang WZ; Wu SY
Biomed Pharmacother; 2017 Jul; 91():999-1005. PubMed ID: 28525949
[TBL] [Abstract][Full Text] [Related]
19. Quantitative control of active targeting of nanocarriers to tumor cells through optimization of folate ligand density.
Tang Z; Li D; Sun H; Guo X; Chen Y; Zhou S
Biomaterials; 2014 Sep; 35(27):8015-27. PubMed ID: 24947231
[TBL] [Abstract][Full Text] [Related]
20. Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets.
Baghbani F; Moztarzadeh F
Colloids Surf B Biointerfaces; 2017 May; 153():132-140. PubMed ID: 28235723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
